Zhejiang Taimei Medical Technology

Taimei Technology's business model is centered on providing cloud-based, software-as-a-service (SaaS) products, eliminating the need for clients to install and maintain software on-premise. The company generates revenue through the sale of these self-developed SaaS products and by offering related professional services in the fields of clinical research, pharmacovigilance, and pharmaceutical marketing. Its clientele includes pharmaceutical companies, contract research organizations (CROs), and research institutes. By March 2024, Taimei had served over 1,400 pharmaceutical firms and CROs, including 21 of the top 25 global pharmaceutical companies.

The company's core offering is its TrialOS platform, a digital collaboration hub designed to connect key industry stakeholders such as pharmaceutical companies, hospitals, service providers, regulatory bodies, and patients. This platform facilitates data exchange and process cooperation by leveraging artificial intelligence, big data, and mobile internet technologies. In addition to TrialOS, the company offers PharmaOS, a digital marketing platform that integrates omnichannel marketing systems to provide data-driven solutions for sales management and customer targeting. Taimei also provides over 40 distinct software products and digital services, including solutions for clinical trial management, data collection and analysis, and pharmacovigilance. These offerings support the entire drug product lifecycle, from R&D to post-market activities.